BACKGROUND: Failure-free survival (FFS) and overall survival (OS) rates were found to improve on Intergroup Rhabdomyosarcoma Study (IRS) IV (IRS-IV) compared with IRS-III for patients with subset 2 (IRS stage 1, group III nonorbit or stage 3, group I/II) low-risk embryonal rhabdomyosarcoma with the addition of cyclophosphamide (total cumulative cyclophosphamide dose of 26.4 g/m 2 ) to the combination of vincristine and dactinomycin (VAC). The goal of Children's Oncology Group ARST0331 for subset 2 low-risk patients was to reduce the total cumulative cyclophosphamide dose without compromising FFS. METHODS: Therapy included 4 cycles of VAC (total cumulative cyclophosphamide dose of 4.8 g/m 2 ) followed by 12 cycles of vincristine and dactinomycin over 46
INTRODUCTION
The Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG) has defined 2 subsets of patients with low-risk rhabdomyosarcoma (RMS), each with an expected 5-year failure-free survival (FFS) rate of 83%. 1 For patients in subset 1, this outcome was achieved with a chemotherapy regimen of vincristine and dactinomycin (VA) on Intergroup Rhabdomyosarcoma Study III (IRS-III).
2 Subset 1 includes patients with localized embryonal RMS (ERMS) that: 1) has been macroscopically resected before the initiation of chemotherapy (group I/II) and arises in either a favorable primary site (IRS stage 1: orbit, nonparameningeal head/neck, non-bladder/prostate genitourinary tract, or hepatobiliary) or in an unfavorable primary site (all sites that are not classified as favorable) and measures 5 cm in size and without lymph node involvement (stage 2); or 2) has not been resected before the initiation of chemotherapy (group III) and arises within the orbit. For patients in subset 2, a 5-year FFS rate of 83% was achieved with the combination of vincristine, dactinomycin, and cyclophosphamide (VAC, total cumulative cyclophosphamide dose of 26.4 g/m 2 ) on IRS-IV. 3 Subset 2 includes patients with localized ERMS that: 1) has been macroscopically resected before the initiation of chemotherapy (group I/II) and arises in an unfavorable primary site and measures >5 cm in size or with regional lymph node involvement (stage 3); or 2) has not been resected before the initiation of chemotherapy (group III) and arises in a favorable primary site other than the orbit (stage 1 nonorbit). We previously reported outcomes using therapy of a shorter duration for low-risk patients in subset 1on COG ARST0331 4 and now report outcomes for low-risk patients in subset 2 of ARST0331.
The 5-year FFS rate for subgroup B low-risk patients on Intergroup Rhabdomyosarcoma Study Group (IRSG) D9602 (subset 2 patients together with patients with stage 1, group IIB/IIC or stage 2, group II ERMS) was 85% when the patients were treated with VAC (total cumulative cyclophosphamide dose of 28.6 g/m 2 ) and a reduced radiotherapy (RT) dose (36 grays [Gy]) compared with IRS-IV (41.4 Gy) for patients with group IIA tumors (microscopic positive margins without regional lymph node involvement). 3, 5 Although IRS-IV and IRSG D9602 therapies were effective for subset 2 patients, their potential long-term toxicities, which can be attributed largely to the total cumulative cyclophosphamide and RT exposures, are concerning for low-risk patients. [6] [7] [8] The primary goal for patients in subset 2 on COG ARST0331 was to estimate the FFS rate using a reduced total cyclophosphamide dose (4.8 g/m 2 ) in combination with VA. A secondary goal was to estimate the local control rate for subset 2 patients with group IIA tumors who received an RT dose of 36 Gy within the setting of reduced cyclophosphamide.
MATERIALS AND METHODS
Eligibility criteria for subset 1 of ARST0331 and required staging studies on ARST0331 have been published previously. 4 Eligibility for subset 2 differed from that for subset 1 only by specific stage and group requirements. We defined stage and group according to Intergroup Rhabdomyosarcoma Study Group guidelines. 3 Patients eligible for subset 2 had stage 1, group III nonorbit or stage 3, group I/II ERMS. Signed written informed consent provided by the patient or guardian following institutional guidelines with Institutional Review Board approval according to the Declaration of Helsinki was required.
The treatment plan for subset 2 of ARST0331 is shown in Table 1 . Delayed surgical resection was encouraged if a group III tumor could be completely resected at week 13. The RT dose was reduced based on the extent of surgical resection (Table 2) . 9 For children aged 2 years, the study permitted RT protocol deviations at the discretion of the treating clinicians based on concerns regarding the long-term morbidity of RT.
Before September 7, 2009 , patients with group III lymph node-negative vaginal tumors were an exception to the RT plan used for patients with tumors at other sites on ARST0331. For these patients, RT was delayed if imaging or vaginoscopy at week 12 of therapy demonstrated that the tumor was shrinking or undetectable. RT was not used if surgical resection did not demonstrate tumor or if any residual tumor was completely removed at week 24. If residual tumor remained in the vagina at week 24, the RT dose was based on the extent of surgical resection as shown in Table 2 . After September 7, 2009, the study was amended so that girls with group III vaginal RMS followed the same RT guidelines as other patients because an increased rate of local failures had been observed. 10 
Statistical Analysis
ARST0331 was a nonrandomized, noninferiority clinical trial. The statistical design has been previously published for subset 1 of ARST0331. 4 The design for subset 2 differed by comparing the primary endpoint of FFS with the fixed expected outcome for patients in subgroup B of IRSG D9602, excluding those with stage 1, group IIB/ IIC or stage 2, group II tumors whose long-term FFS was expected to be 83% at the time that ARST0331 was written, using the formula S(t) 5 0.83 1 0.17*exp(-1.00*t). 5 A cure model was used to develop the required sample size. A total of 100 subset 2 patients would provide 80% power (testing at the 15% significance level, 1-sided) to detect a decrease in FFS from 83% to 75% associated with the reduction in therapy. We compared FFS and overall survival (OS) curves for subset 2 using the log-rank test. 11 The 95% confidence intervals (95% CI) were determined using the Greenwood formula. 12 Results were based on data available as of June 30, 2014. 
RESULTS

The
Patients
Patient characteristics are shown in Table 3 . The majority of patients were aged <5 years (46 patients; 70%) and female (44 patients; 67%), and had stage 1 (45 patients; 68%), group III (45 patients; 68%) tumors that were noninvasive (44 patients; 67%), measuring > 5 cm (39 patients, 59%), and known to be without lymph node involvement (53 patients; 80%). The most common primary tumor sites were the female genital tract (21 patients [18 in the vagina, 2 in the uterus, and 1 in the cervix]; 32%), nonparameningeal head/neck (12 patients; 18%), and hepatobiliary (9 patients; 14%). A total of 59 patients (89%) had group II or III tumors, 24 of whom (41%) did not receive RT; 14 of these patients did not receive RT as allowed by protocol guidelines (12 with tumors of the female genital tract and 2 who were aged 2 years), 3 patients did not receive RT against protocol guidelines, and 7 patients were taken off protocol therapy before scheduled RT. Five patients with group III vaginal tumors were enrolled after September 7, 2009; 4 received RT and 1 was taken off protocol therapy before scheduled RT. Among the 13 patients with group IIA RMS, 6 did not receive RT: 2 were aged 2 years and did not receive RT as allowed by protocol guidelines, 3 did not receive RT against protocol guidelines, and 1 patient was taken off protocol therapy before scheduled RT. There were 2 minor RT protocol deviations and 1 major RT protocol deviation in 2 patients with group IIA RMS who were treated with RT.
Of the 45 patients with group III tumors, 22 (49%) underwent delayed surgical procedures, including 17 girls with genital tract RMS (15 in the vagina, 1 in the uterus, and 1 in the cervix). There were no deviations from the protocol-directed surgical approach to delayed surgical resection in patients with group III tumors identified. Sixteen of the 22 patients (73%) were tumor free or with microscopic tumor only after the delayed surgical procedure and received a reduced RT dose (36 Gy) or no RT (Table 2) ; resection margins were unknown for 3 patients. Only 6 of the 21 girls with group III genital tract RMS were treated with RT.
Outcomes
With a median follow-up of 3.5 years, there were 20 failures compared with 10.53 expected failures under the null hypothesis if the FFS rate for patients in subset 2 of ARST03331 was the same as that for similar patients treated on IRSG D9602. The estimated 3-year FFS and OS rates for subset 2 patients on ARST0331 were 70% (95% CI, 57%-80%) and 92% (95% CI, 83%-97%), respectively (Fig. 1) . Fifty-five of the 78 subgroup B patients on IRSG D9602 met subset 2 stage and group requirements. The corresponding 3-year FFS and OS rates for these similar patients on IRSG D9602 were 83% (95% CI, 70%-91%) and 90% (95% CI, 79%-96%), respectively. The estimated 3-year FFS rate for girls with subset 2 genital tract tumors (21 patients) on ARST0331 was 57% (95% CI, 33%-75%) compared with 77% (95% CI, 61%-87%) for all other subset 2 patients (45 patients) (P 5 .02) (Fig. 2 Top) . The estimated 3-year OS rate for girls with subset 2 genital tract tumors (21 patients) was 95% (95% CI, 69%-99%) compared with 91% (95% CI, 78%-97%) for all other subset 2 patients (P 5 .21) (Fig. 2 Bottom). The estimated 5-year OS rate for subset 2 patients on ARST0331 was 87% (95% CI, 77%-97%), and the 5-year OS rate for subgroup B patients on IRSG D9602 who met subset 2 stage and group requirements was 88% (95% CI, 83%-97%).
Disease Recurrences
At the time of last follow-up, there were 20 recurrences (10 in patients with primary tumors of the female genital tract and 10 in patients with primary tumors arising in other primary sites) and 8 disease-related deaths (1 in a patient with a primary tumor of the female genital tract and 7 in patients with primary tumors arising in other primary sites) reported. There were 14 local recurrences, 2 locoregional recurrences, 1 local plus distant recurrence, 1 regional recurrence, and 2 distant recurrences. Local failure occurred in 9 of 21 girls with genital tract tumors (43%) and in 8 of 45 of the remaining subset 2 patients (18%). There were 8 recurrences reported among 15 girls with genital tract tumors who did not receive RT and 1 recurrence reported among 6 girls with genital tract tumors who received RT. There were 4 recurrences (2 local, 1 locoregional, and 1 local plus distant recurrence) among 13 patients with stage 3, group IIA tumors. Two of the 4 patients who experienced a recurrence did not receive RT, 1 of whom was aged 2 years.
Toxicity
There was one patient with hepatobiliary RMS who developed sinusoidal obstruction syndrome after RT, which was classified as moderately severe using criteria that we have previously published. 4 We did not observe any unexpected grade 4 toxicities according to the National Cancer Institute's Common Terminology Criteria for Adverse Events or toxic deaths.
DISCUSSION
To limit the toxicity for subset 2 low-risk RMS patients, we reduced the total cyclophosphamide dose on ARST0331 to 4.8 g/m 2 , a dose that would be expected to preserve fertility in the majority of patients. 6, 7 Using this approach, the 3-year FFS rate was 70% (95% CI, 57%-80%) compared with a 3-year FFS rate of 83% (95% CI, 70%-91%) for similar patients when treated with a more intensive VAC regimen (total cumulative cyclophosphamide dose of 28.6 g/m 2 ) on IRSG D9602. We consider the overall FFS for all subset 2 low-risk RMS patients on ARST0331 to be suboptimal, especially for girls with genital tract RMS.
The 3-year FFS was significantly worse for girls with genital tract tumors compared with patients with tumors in other primary sites, suggesting that the local control guidelines that eliminated RT for patients with group III vaginal RMS in combination with the lower total cyclophosphamide dose contributed to the suboptimal outcome. The 2-year cumulative incidence of local recurrence was 43% among girls with group III vaginal RMS following protocol guidelines before September 7, 2009 , as reported previously. 10 We subsequently amended ARST0331 to require RT for patients with group III vaginal RMS, following the same paradigm that was used for other disease sites. Only 5 patients with group III vaginal RMS were enrolled onto the study after the amendment. Therefore, our experience is too limited to reach a conclusion regarding the efficacy of RT with or without delayed surgical resection within the setting of a reduced total cyclophosphamide dose of 4.8 g/m 2 for patients with vaginal RMS.
Although FFS was suboptimal for patients with subset 2 low-risk RMS on ARST0331, the 3-year OS rate was comparable between subset 2 patients on ARST0331 (92%; [95% CI, 83%-97%]) and IRSG D9602 (90% [95% CI, 79%-96%]). The 5-year OS rate also was comparable between subset 2 patients on ARST0331 (87% [95% CI, 78%-97%]) and IRSG D9602 (88% [95% CI, 83%-97%]). In addition, the 3-year OS rate was similar on ARST0331 between girls with genital tract RMS (95% [95% CI, 69%-99%]) and patients with tumors at other primary sites (91% [95% CI, 78%-97%]) (P 5 .21). Debate continues among cooperative groups in Europe and North America with regard to the optimal endpoint for low-risk RMS studies. 13 The COG Soft Tissue Sarcoma Committee has used FFS as the primary endpoint for studies of therapy reduction in patients with low-risk RMS with the objective of preventing disease recurrence and the need for salvage therapy, which usually is more toxic and may not be successful as often as initial therapy. 14 We did not collect data regarding salvage therapy that was used after disease recurrence on ARST0331. In contrast, a goal of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 89 (MMT 89) study was to reduce local therapy and its toxicity for patients with localized RMS, and OS was used as the primary endpoint. 15 Their design accepted the possibility of poorer FFS and the need for salvage therapy for those patients who develop disease recurrence. For example, patients with orbital RMS on MMT 84 and MMT 89, which eliminated RT if a complete response was achieved with chemotherapy, had a 10-year event-free survival rate of 58% and a 10-year OS rate of 85%, whereas patients with orbital RMS on IRS-II, IRS-III, and IRS-IV, which used primary RT for patients with group II/III tumors, had a 10-year event-free survival rate of 86% and a 10-year OS rate of 88%. 16 Therefore, a subset of patients with orbital RMS were cured without local therapy and its toxicity on the MMT studies. However, using this approach, another subset of patients underwent additional treatment for disease recurrence. The impact of these philosophical differences in study design on the quality of survival for low-risk patients will only be addressed through studies directed at these populations after years of follow-up. We do not believe the suboptimal FFS and burden of subsequent salvage therapy justifies the therapy used on ARST0331 for subset 2 patients.
A local failure rate of 26% (17 of 66 patients) among subset 2 patients on ARST0331 is unacceptably high, including 43% for girls with genital tract tumors and 18% for all other subset 2 patients. Given the high local failure rates for subset 2 patients on ARST0331, the results of the current study support a role for cyclophosphamide in local control for these patients. Indeed, our experience with patients with group IIA or group III N0 vaginal RMS on IRSG D9602 and ARST0331 who did not receive RT also demonstrated a higher rate of local recurrence when less cyclophosphamide is given. 10 Both IRSG D9602 and ARST0331 tested a reduced RT dose (36 Gy) compared with IRS-IV (41.4 Gy) for patients with group IIA tumors. There were only 13 subset 2 patients with group IIA tumors on ARST0331. We were unable to assess the efficacy of an RT dose of 36 Gy for subset 2 patients with group IIA tumors because of the following factors: the small number of stage 3, group IIA patients; the high percentage of stage 3, group IIA patients who did not receive RT; and the suboptimal total cyclophosphamide dose.
We believe that quality of outcome could be assessed for patients with low-risk RMS by taking FFS, OS, and toxicity into account. We achieved a favorable balance for subset 1 patients (stage 1/2, group I/II or stage 1, group III orbital ERMS) using ARST0331 therapy, including 22 weeks of VAC (total cumulative cyclophosphamide dose of 4.8 g/m 2 ) followed by VA and RT for patients with group II/III tumors. We do not believe we have achieved a favorable balance for subset 2 patients given their suboptimal FFS on ARST0331 when using a reduced total cyclophosphamide dose of 4. of cyclophosphamide. 17 For girls with group III genital
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